• Home
  • News
  • CaremarkPCS Health Allegedly Ignored 'Specialty Drugs' Requirements

CaremarkPCS Health Allegedly Ignored 'Specialty Drugs' Requirements

A proposed class action lawsuit claims defendant CaremarkPCS Health, L.L.C. violated California consumer protection laws. At the heart of the 30-page complaint is Enbrel, an expensive drug used to treat five long-term inflammatory diseases, as well as all other refrigerated specialty drugs dispensed and shipped by the defendant. Enbrel, the lawsuit says, must be stored and maintained between 36 and 46 degrees Fahrenheit.

The plaintiff alleges the defendant, despite being well aware of Enbrel and other specialty drugs’ particular temperature needs, does not have adequate policies in place to ensure such medications are “maintained within that drug’s required temperature range during storage and distribution.” The lawsuit takes particular aim at the defendant’s alleged failure to store and distribute its specialty drugs at the correct temperature ranges during transit; its alleged failure to disclose that mail-order pharmacies (like the defendant) do have appropriate policies and procedures to ensure specialty drugs are properly maintained and shipped; and, among other allegations, its alleged failure “to disclose that specialty drugs shipped by specialty pharmacies [such as the defendant] may freeze during transit and [are] no longer suitable for use.”

The case lists the below “specialty drugs” as possibly being affected by the defendant’s conduct:

  • Actimmune (interferon gamma 1B)
  • Avonex (interferon beta-1a)
  • Betaseron (interferon beta 1B)
  • Copaxone (glatiramer)
  • Enbrel (etanercept)
  • Epogen (epoetin alfa)
  • Genotropin (somatropin)
  • Humatrope (somatropin)
  • Humira (adalimumab)
  • Infergen (interferon alfacon-1)
  • Kaletra (lopinavir/ritonavir)
  • Neulasta (pegfilgrastim)
  • Neupogen (filgrastim)
  • Norditropin (somatropin)
  • Norvir (ritonavir)
  • Procrit (epoetin alfa)
  • Rapamune (sirolimus)
  • Rebetol (ribavirin)
  • Sandostatin (octreotide)
  • Sandostatin LAR (octreotide) 

Before commenting, please review our comment policy.

Stop H.R. 985

A reckless new bill represents an unprecedented threat to consumer rights, essentially gutting class action and mass tort litigation. Congress has tried to ram it through without us noticing. Read more about the implications of this bill, and contact your members of Congress to protect your rights.

Blog Categories

Sign Up For Our Newsletter

New cases and investigations, settlement deadlines, and news - straight to your inbox.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, programmers and writers) with years of experience in the legal industry. We work closely with class action and mass tort attorneys across the country and help with investigations into corporate wrongdoing.